. Author manuscript; available in PMC: 2018 May 1.

Published in final edited form as: Cancer. 2017 Mar 3;125(5):332–340. doi: 10.1002/cncy.21841

Table 2. CEC positivity by diagnostic grouping.

	n	CEC+ n(%)	CEC susp. n(%)	CEC- n(%)	p
Malignant	136	69 (50.7%)	21 (15.4%)	46 (33.8%)	0.44
Benign	35	22 (62.9%)	3 (8.6%)	10 (28.6%)
Neoplastic	158	85 (53.8%)	21 (13.3%)	52 (32.9%)	0.56
Non-neoplastic	13	6 (46.2%)	3 (23.1%)	4 (30.8%)
PDAC	108	53 (49.1%)	19 (17.6%)	36 (32.7%)	0.47
NET	9	6 (66.7%)	2 (22.2%)	1 (11.1%)

CEC: Circulating epithelioid cells. +: Positive. Susp: suspicious. -: Negative. PDAC: Pancreatic ductal adenocarcinoma. NET: Neuroendocrine tumor.